Cis-diamminedichloroplatinum II in advanced urothelial cancer.
Thirteen patients with advanced urothelial cancer received a minimum of 2 courses of cis-diamminedichloroplatinum II. Of these patients 6 (46 per cent) achieved a partial response with an average duration of more than 6 months. One patient has received cis-diamminedichloroplatinum for more than 1 year and has no clinical evidence of tumor (complete response in lung metastasis plus excision of local recurrence). The routine administration of intravenous fluids and mannitol immediately before cis-diamminedichloroplatinum prevented the nephrotoxicity associated with this drug. An outpatient setting was well tolerated in most instances. This report confirms the activity of cis-diamminedichloroplatinum in urothelial cancer and suggests its use as an adjuvant to operation and/or radiotherapy in selected cases.
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D008353:Mannitol / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014571:Urologic Neoplasms / Q000188:drug therapy*
D008353:Mannitol; D002945:Cisplatin